<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185209</url>
  </required_header>
  <id_info>
    <org_study_id>PERI-IMPL</org_study_id>
    <nct_id>NCT02185209</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics</brief_title>
  <official_title>Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics A Prospective, Double Blind, Randomized, Three Armed, Parallel, Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margareta Hultin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the use of systemic adjunctive antibiotics in
      the treatment of periimplantitis is needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will give the opportunity to draw scientifically based conclusions on the
      recommendations of the use of adjunctive systemic antibiotics in the treatment of
      peri-implantitis. This study will also be able to determine the ecological impact on the
      oropharyngeal and intestinal microflora between different antibiotic treatments. The lack of
      knowledge in this area has been highlighted by the Food and Drug Administration and The
      Swedish Council on Health Technology Assessment (SBU)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probing pocket depth change and bone level stability</measure>
    <time_frame>0,6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of clinical soft tissue inflammation, bleeding on probing (BOP)</measure>
    <time_frame>0, post operative 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft tissue recession (REC) and clinical attachment level gain (CAL)</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Quantitative and qualitative change in levels of the peri-implant periopathogenic microflora</measure>
    <time_frame>0,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Susceptibility changes of the oral and intestinal microflora to amoxicillin, metronidazole and penicillin.</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative and qualitative changes in the oral and intestinal microflora</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of amoxicillin, metronidazole and PcV in saliva and feces</measure>
    <time_frame>0, 6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Follow-up of adverse events related or unrelated to the investigated medical products</measure>
    <time_frame>0,6, and 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Periodontal Diseases</condition>
  <condition>Periimplantitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Place capsule to mimic antibiotics</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Sandoz</intervention_name>
    <description>Tablet 500 mg amoxicillin Sandoz three times a day</description>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Sanofi</intervention_name>
    <description>400 mg metronidazole Sanofi administered three times a day (TID)</description>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenoxymethylpenicillin Meda</intervention_name>
    <description>1600 mg phenoxymethylpenicillin Meda, three time a day (TID)</description>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥18-65 year

          2. Patients who has been referred by a general dentist to a specialist clinic in
             periodontology for treatment of peri-implantitis.

          3. Having sign of peri-implantitis around at least one osseointegrated dental implant
             that has been in function for ≥ one year

          4. Peri-implantitis is diagnosed when; PPD of ≥ 6mm can be found at a dental implant in
             association with BOP and/or suppuration together with the loss of marginal alveolar
             bone of more than 2 mm detected on intraoral radiographs (giving radiographic exposure
             of at least ≥ 3 fixture threads).

          5. Partially or completely edentulous subjects with healthy or treated periodontal
             conditions enrolled in a regular supportive program.

          6. Full-Mouth Plaque Score (FMPS) ≤ 25

          7. Signed informed consent

        Exclusion Criteria:

          1. Known allergy to amoxicillin, penicillin (PcV), metronidazole or betalactamic

          2. Contraindication for dental surgical treatment (i.e. immunocompromised, uncontrolled
             DM (B-GHb-A1C 8-9 %, 64-75 mmol/mol), osteoporosis, I.V bisphosphonate treatment due
             to malignancy, pregnant and lactating women).

          3. Incapability to perform basal oral hygiene measures due to physical or mental
             disorders.

          4. Received systemic antimicrobial therapy in the past three months.

          5. Currently on allopurinol, digoxin, disulfiram, lithium, busulfan, 5-fluorouracil,
             methotrexate, phenytoin, cyclosporine and warfarin.

          6. Known severe chronic peripheral or central disease of the nervous system

          7. Known alcohol abuse

          8. Known hepatic encephalopathy

          9. Known lactose intolerance, galactose intolerance

         10. Untreated periodontal condition.

         11. Implant showing sign of mobility.

         12. Implants with bone loss exceeding 2/3 of the length of the implant or implants with
             bone loss beyond any transverse openings in hollow implants.

         13. Any medical condition or on any concomitant medication that, in the opinion of the
             investigator, might interfere with the evaluation of the study objectives or
             jeopardize patient safety

        Patients with xerostomia or having slow bowel motion will be excluded from the group of
        patients providing salivary and fecal samples.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Hultin, DDSass. prof</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institute, Dental medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bodil Lund, DDSass.prof</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institute, Dental Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalia Kahlil, DDS, PhDstud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Dental Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margareta Hultin, DDS, ass. prof</last_name>
    <phone>+46 (0)8-524 882 48</phone>
    <email>margareta.hultin@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bodil Lund, DDS prof</last_name>
    <email>bodil.lund@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Folktandvården Skanstull</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Grundström, O.D</last_name>
      <email>Caroline.Grundström@ftv.sll.se</email>
    </contact>
    <investigator>
      <last_name>Caroline Grundström, O.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leif Jansson, O.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Folktandvården Kaniken</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 753 09</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saeed Shamani, O.D</last_name>
      <phone>+46(0)18 611 63 80</phone>
      <email>saeed.shamani@ki.se</email>
    </contact>
    <investigator>
      <last_name>Britt-Marie Herdevall, O.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Margareta Hultin</investigator_full_name>
    <investigator_title>DDS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Penicillin V</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

